Clinical Trials Logo

Retinal Artery Macroaneurysm clinical trials

View clinical trials related to Retinal Artery Macroaneurysm.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05716932 Completed - Clinical trials for Retinal Artery Macroaneurysm

Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.

RAM
Start date: December 22, 2022
Phase:
Study type: Observational

Treatment options for Retinal artery Macroaneurysm (RAM) include focal laser photocoagulation, intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) injection, combined anti VEGF - laser therapy, YAG hyaloidotomy and pars plana vitrectomy. Focal laser photocoagulation is applied directly to the macroaneurysm (direct lesional), its surrounding area (indirect perilesional) or a combination of both. [3-5] Anti-VEGF agents including bevacizumab and ranibizumab reduce leakage from the macroaneurysm. [3-15] YAG hyaloidotomy is used for fresh premacular hemorrhage. [16] Pars plana vitrectomy is reserved for RAM complicated by vitreous and/or premacular hemorrhage. [17] However, there is no consensus about laser and anti VEGF treatments. Some authors use perilesional laser, while others use direct laser only. There is also no clear protocol for anti VEGF injections. Some authors report using focal laser only if multiple anti VEGF injections do not result in marked improvement. [3-17] .